Latest Manufacturing And Supply Chain News

Skellerup Holdings delivered a tenth consecutive year of EBIT growth with a 14% rise to NZD 89.3 million and expanded its climate initiatives, reporting a 24% jump in net profit to NZD 67.7 million.

Breville Group delivered record FY26 revenue of AUD 1.81 billion and EBIT of AUD 207 million, navigating tariff volatility and currency headwinds while completing a major manufacturing diversification.

KTEK Aerosystems has leveraged its $10 million IPO to accelerate production scale-up and international growth, with deliveries set to resume in September and a new US assembly operation underway.

MyEco Group has finalised its operational overhaul, consolidating manufacturing in China and cutting fixed costs to sharpen its focus on sustainable packaging growth.

Neurizon Therapeutics has secured a critical five-year supply agreement with Elanco Animal Health for GMP-grade monepantel, underpinning the commercialisation readiness of its lead ALS drug candidate NUZ-001.

Memphasys has locked in a 12-month exclusive supply agreement with Monash IVF for its Felix™ sperm selection system, marking its biggest commercial contract to date and setting a foundation for recurring revenue.

Saferoads Holdings (ASX: SRH) has acquired Chameleon AMLS, adding a new modular trailer product line and appointing its founder Andrew Kaye to the board.

OD6 Metals is progressing its acquisition option for the Quinn Fluorspar Project in Nevada, a high-grade fluorspar asset poised to address the United States' complete import reliance on this critical mineral vital to semiconductor, battery, and defense sectors.

AML3D has installed its first portable ARCEMY additive manufacturing system at the US Navy's Additive Manufacturing Centre of Excellence, marking a milestone in its partnership with Austal USA and expanding its footprint in military-grade 3D printing.

BluGlass has embarked on a A$1.25 million development program with a major US defence prime, receiving an initial A$560,000 order to develop cutting-edge visible GaN lasers for aerospace and defence applications.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

CSL Limited announces the retirement of CEO Dr Paul McKenzie, with veteran executive Gordon Naylor appointed as interim CEO and Managing Director. The leadership change marks a new chapter for the biotech giant amid ongoing strategic transformation.